1 Medische Technologie Markt, technologie en toekomstige thema s Auteur: Chris Maliepaard Versie: 1.1 Datum: 24 septembe
A pharmacist’s functions in clinical pharmacogenomics will vary, depending on education, training, experience, and the needs of the practice setting. All pharmacists should have a basic understanding of pharmacogenomics in order to provide patient care that incorporates pharmacogenomic recommendations. Pharmacogenomics is about selecting the “right drug in the right amount for the right patient.” In metastatic colorectal cancer, germline pharmacogenomics testing presents a unique opportunity to improve outcomes, since the genes dihydropyrimidine dehydrogenase and UDP-glucuronosyltransferase metabolizing the chemotherapy drugs, 5-fluorouracil, and irinotecan are already well known. Abstract. Aim of the Review To assess the state of the literature concerning pharmacogenomic testing in patients requiring vitamin K antagonists, specifically warfarin.Method We conducted a literature search of MEDLINE and International Pharmaceutical Abstracts using the following words: warfarin, pharmacogenetic, and pharmacogenomic. The search results were reviewed by the authors and papers ABSTRACTGenetics may account for much of the variability in our patients’ responses to drug therapies. This article offers the clinician an up-to-date overview of pharmacogenomic testing, discussing implications and limitations of emerging validated tests relevant to the use of warfarin (Coumadin), clopidogrel (Plavix), statins, tamoxifen (Nolvadex), codeine, and psychotropic drugs. The incidence of type 2 diabetes (T2D) and its costs to the health care system continue to rise. Despite the availability of at least 10 drug classes for the treatment of T2D, metformin remains the most widely used first-line pharmacotherapy for its treatment; however, marked interindividual variability in response and few clinical or biomarker predictors of response reduce its optimal use.
Pharmacogenomics combines conventional pharmaceutical sciences such as biochemistry with understanding of genes, proteins, and single nucleotide polymorphisms. By doing so, pharmacogenomics aims to optimize drug therapy, with respect to the patients' genotype, which would result in maximum effectiveness and minimum side effects. Download full-text PDF. Pharmacogenomics: Application to the Management of Cardiovascular Disease. as are guidelines for incorporation of genetic information into patient-care decisions. These PHARMACOGENOMICS: APPLICATIONS TO PATIENT CARE SECOND EDITION ciccp American College of Clinical Pharmacy Lenexa, Kansas. Pharmacogenomics in Drug Discovery and Drug Development 107 Joseph R. Walker, Pharm.D. SECTION TWO-PHARMACOGENOMICS APPLICATIONS IN TREATING DISEASE CHAPTER 8 Pharmacogenomics of Solid Tumors 123 JillM. Kolesar, Pharm.D Download full-text PDF. Introduction To Pharmacogenomics. Article pharmacists to gain an understanding of this field and clinical applications of this science, particularly as it relates to Download full-text PDF. Pharmacogenomics: Application to the Management of Cardiovascular Disease. as are guidelines for incorporation of genetic information into patient-care decisions. These Integrating pharmacogenomics into pharmacy practice via to improving patient care, achieving better outcomes, and enhancing health care delivery. As PHC evolves and is integrated into practice, patients are benefiting from the application of genetic information. One of the
Pharmacogenomics uses information about a person's genetic makeup, or genome, to choose the drugs and drug doses that are likely to work best for that particular person. This new field combines the science of how drugs work, called pharmacology, with the science of the human genome, called genomics Pharmacogenomics and Patient Care: One Size Does Not Fit All. A transformation of this magnitude most likely will involve the application of preemptive genotyping or whole-genome sequencing and incorporation of genetic information into the patients’ electronic medical records, which can then be used for future genomic information–based Furthermore, providers may not be comfortable counseling patients on PGx results due to their lack of direct experience with the tests. Therefore, this program will be geared on the novice learner, and work to build and enhance pharmacists’ understanding of the current state of evidence for incorporating pharmacogenomics into patient care plans. Pharmacogenomics promises to change this way of prescribing to a customized approach that uses genetic information to predict an individual’s response to medications. It is one piece of an overall initiative to personalize patient care based on the patient’s individual characteristics and preferences. "Translational Software has taken the pioneering step of implementing the first pharmacogenomics solution that employs FHIR genomics for optimizing the prescription of patient medications, and has been a real leader in this arena." GIL ALTEROVITZ, PHD Challenges to future pharmacogenomics and its translation into individualized medicine, drug development, and regulation are discussed. For example, knowledge on genetic determinants of disease pathogenesis and drug action, especially those of complex disease and drug response, is not always available.
Pharmacogenomics is about selecting the “right drug in the right amount for the right patient.” In metastatic colorectal cancer, germline pharmacogenomics testing presents a unique opportunity to improve outcomes, since the genes dihydropyrimidine dehydrogenase and UDP-glucuronosyltransferase metabolizing the chemotherapy drugs, 5-fluorouracil, and irinotecan are already well known. Abstract. Aim of the Review To assess the state of the literature concerning pharmacogenomic testing in patients requiring vitamin K antagonists, specifically warfarin.Method We conducted a literature search of MEDLINE and International Pharmaceutical Abstracts using the following words: warfarin, pharmacogenetic, and pharmacogenomic. The search results were reviewed by the authors and papers ABSTRACTGenetics may account for much of the variability in our patients’ responses to drug therapies. This article offers the clinician an up-to-date overview of pharmacogenomic testing, discussing implications and limitations of emerging validated tests relevant to the use of warfarin (Coumadin), clopidogrel (Plavix), statins, tamoxifen (Nolvadex), codeine, and psychotropic drugs. The incidence of type 2 diabetes (T2D) and its costs to the health care system continue to rise. Despite the availability of at least 10 drug classes for the treatment of T2D, metformin remains the most widely used first-line pharmacotherapy for its treatment; however, marked interindividual variability in response and few clinical or biomarker predictors of response reduce its optimal use. Handbook of Pharmacogenomics and Stratified Medicine is a comprehensive resource to understand this rapidly advancing field aiming to deliver the right drug at the right dose to the right patient at the right time. It is designed to provide a detailed, but accessible review of the entire field from basic principles to applications in various diseases. In recent years, commercially available pharmacogenomic tests have been approved by the Food and Drug Administration (FDA), but their application in patient care remains very limited. More generally, the implementation of pharmacogenomics in routine clinical practice presents significant challenges.
Guidelines for optimization of PGx testing are available for a number of drug-gene pairs, and evidence supporting the clinical utility of this service is growing in specific patient contexts. This report reviews a variety of patient care situations in which evidence is emerging to show patient benefit from pharmacogenomic (PGx) testing.
